INmune Bio Inc(INMB)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.17 (+4.33%), 시가총액 $0.04B, 52주 범위 $1.12 ~ $8.09.
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic
INmune Bio Inc의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
INmune Bio Inc의 현재 주가는 $2.17 (+4.33%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
INmune Bio Inc의 시가총액은 약 $0.04B입니다.
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commer